B Cell Lymphoma


Predicting early outcomes in DLBCL

Measurement of circulating tumor DNA (ctDNA) could be a new and useful tool for predicting survival outcomes and response to therapy in patients...

From the Journals

ctDNA predicts early outcomes in DLBCL

Adding measurements of circulating tumor DNA to established risk factors could help create a profile of an overall picture of likely outcomes.